JAB-3068 has the potential to reduce tumor burden by enhancing CD8+ antitumor immunity through cytotoxic T-cells, indicating possible therapeutic promise for NSCLC, CRC, and esophageal squamous cell carcinoma (ESCC) when used in combination with an anti-PD1 antibody. This evidence concerns the gene PDCD1 and neoplasm.